• Barrett's esophagus: data support surveillance for indefinite dysplasia

    Current guidelines were based on expert opinion.

  • HPV+ oropharynx cancer: de-intensified CRT does well in phase 2

    Data suggest that less is more in properly selected patients.

  • Oropharynx SCC: TORS, radiotherapy yield similar QoL in randomized trial

    Toxicity profiles differ between the 2 approaches.

  • Inflammatory biomarkers predict survival in small-cell esophageal cancer

    PLR can help identify high-risk patients for more aggressive treatment.

  • FDA approves pembrolizumab for advanced esophageal cancer

    Action based on response rate and durability in patients with refractory disease.

  • In GI neuroendocrine neoplasms with liver metastasis, primary tumor resection linked to better survival

    Consider PTR in these patients, but factor age and primary tumor site, size, and differentiation into the decision.

  • Obstructive sleep apnoea linked to oesophageal cancer risk

    Severe obstructive sleep apnoea may indicate the need for endoscopic screening for Barrett's oesophagus.

  • ESMO GI 2019: endoscopy vs. surgery for early oesophageal cancer
    ESMO GI 2019: endoscopy vs. surgery for early oesophageal cancer

    Study highlights “surprisingly low” risk of lymph node metastases and micrometastases with endoscopic treatment.

  • In esophageal cancer with positive lymph nodes, adjuvant therapy may help

    The study uses a larger and more detailed database than previous work.

  • Esophageal cancer: PET/CT surveillance useful even in absence of clinical suspicion

    About half of esophageal cancers recur within 2 years after surgery with curative intent.

  • Lapatinib too toxic in HER2+ gastroesophageal adenocarcinoma

    First phase 2 randomized trial of add-on lapatinib with perioperative chemotherapy.

  • Esophageal cancer: no benefit for cervical lymph node dissection

    No survival benefit, higher rate of recurrent laryngeal nerve palsy.

  • ESMO guideline now includes FLOT for gastric cancer

    A change in the standard of care.

  • Hormonal factors influencing risk of gastrointestinal cancer
    Hormonal factors influencing risk of gastrointestinal cancer

    Data from the European Prospective Investigation into Cancer and Nutrition cohort.

  • ESTRO 2019 – Dose intensity affects the pathological response in patients with oesophageal cancer treated with neoadjuvant CRT

    Results from a large multi-institutional analysis highlight the major role of radiation dose in the choice of the optimal treatment for oesophageal cancer

  • HIV-infected veterans are at higher risk for some subtypes of oesophageal, but not gastric cancer

    In male veterans, HIV infection is associated with a higher risk for oesophageal squamous cell carcinoma, especially when CD4 count is low, but not with oesophageal adenocarcinoma or gastric cancer after adjusting for confounders.

  • Cervical esophageal cancer: chemoradiation as an alternative to surgery

    CCRT may be a "reasonable" option, with salvage surgery for residual disease.

  • Load more